Mapping the core region of Aβ binding to the LilrB2 D1D2 domains. A 200-residue recombinant LilrB2 segment spanning the D1 and D2 domains (LilrB2 D1D2) was used in our study, and oligomeric human Aβ 1-42 (Aβ42) was prepared by incubating 10 μ M Aβ42 at 37 °C overnight ( Supplementary Fig. 1 ). LilrB2 D1D2 selectively binds oligomeric Aβ42 as previously reported 26 ( Supplementary Fig. 2 ).
A ggregated amyloid-β (Aβ) is found in large amounts in the autopsied brains of Alzheimer's disease (AD) patients, and it is widely considered a key factor in triggering neural degeneration in AD 1, 2 . The long-standing amyloid cascade hypothesis has been challenged in recent years by the lack of correlation between Aβ accumulation and cognitive impairment in elderly patients and the better correlation between histopathological changes of neurofibrillary tangles (aggregation of tau) and loss of cognition [3] [4] [5] . However, three major findings continue to support the hypothesis: Aβ overproduction is found in nearly all familial forms of AD 6, 7 , the oligomeric form of Aβ is toxic to neurons [8] [9] [10] , and overexpression of Aβ and APP (amyloid precursor protein) mutants in animal models leads to the development of AD-related phenotypes 11, 12 . Recent AD-related studies continue to support the key role of Aβ 13, 14 .
Extensive work has focused on developing inhibitors of Aβ toxicity as potential therapeutic drugs for AD. Most of these target Aβ aggregation [15] [16] [17] , reduce the production of Aβ through inhibition of βor γ -secretase [18] [19] [20] , or reduce Aβ levels through immunotherapy 21,] 22 . Recent studies suggest that one or more high-affinity protein receptors on the neuronal cell surface, such as cellular prion protein (PrP C23 ) and ephrin type B receptor 2 (EphB2 24 ), are responsible for the recruitment of Aβ oligomers and subsequent neurotoxicity 25 . These findings have sparked interest in illuminating the molecular mechanism of Aβ-receptor recognition, with the hope that this information will lead to the development of new, effective AD therapeutics that inhibit the interaction of Aβ with neuron cell receptors.
Among all these cell surface Aβ receptors 25 , LilrB2 is one of a few receptors that are reported to be promising therapeutic targets for the treatment of AD, based on the observation that genetic depletion of the murine homologue, PirB (PirB −/− ), rescues Aβ-induced AD-related phenotypes in multiple model systems from cultured cortical neurons to transgenic mice, including recognition memory defects in APP/PS1 mice 26 . The two amino-terminal extracellular immunoglobulin domains (D1D2) of LilrB2 and its murine homologue PirB selectively bind Aβ oligomers with nanomolar affinity. LilrB2 protein is detected in human brains of both AD patients and non-AD adults, with no significant difference in expression level, but its downstream signalling is altered in AD brains, implicating LilrB2 in Aβ-dependent synaptic loss 26 . Here, we identify the binding moieties of both Aβ oligomers and LilrB2 and present a model for their interaction. Based on the structural model, we designed Aβ-LilrB2 interaction inhibitors by computationally selecting molecules to compete with Aβ for the LilrB2 binding sites. The resulting compounds inhibited the interaction between oligomeric Aβ and LilrB2 with up to high nanomolar K i and low micromolar half maximum inhibitory concentration (IC 50 ) values. They also showed the ability to inhibit LilrB2-induced Aβ-cell contact, and therefore to inhibit Aβ cytotoxicity.
Inhibiting the interaction between amyloid-β (Aβ) and a neuronal cell surface receptor, LilrB2, has been suggested as a potential route for treating Alzheimer's disease. Supporting this approach, Alzheimer's-like symptoms are reduced in mouse models following genetic depletion of the LilrB2 homologue. In its pathogenic, oligomeric state, Aβ binds to LilrB2, triggering a pathway to synaptic loss. Here we identify the LilrB2 binding moieties of Aβ ( 16 KLVFFA 21 ) and identify its binding site on LilrB2 from a crystal structure of LilrB2 immunoglobulin domains D1D2 complexed to small molecules that mimic phenylalanine residues. In this structure, we observed two pockets that can accommodate the phenylalanine side chains of KLVFFA. These pockets were confirmed to be 16 KLVFFA 21 binding sites by mutagenesis. Rosetta docking revealed a plausible geometry for the Aβ-LilrB2 complex and assisted with the structure-guided selection of small molecule inhibitors. These molecules inhibit Aβ-LilrB2 interactions in vitro and on the cell surface and reduce Aβ cytotoxicity, which suggests these inhibitors are potential therapeutic leads against Alzheimer's disease.
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To map the binding core of Aβ, we developed an enzyme-linked immunosorbent assay (ELISA)-based interaction assay that enables high-throughput detection of the Aβ-LilrB2 interaction. We immobilized LilrB2 D1D2 on an ELISA plate and measured the amount of bound Aβ segments by Aβ-specific antibodies or the fluorescence signal of fluorescein conjugated to the segments. We found the LilrB2 D1D2 domains bind to Aβ42 and its amino-terminal moiety Aβ 1-21 , but not to Aβ 1-15 ( Fig. 1 and Supplementary Table 1 ). We also found that the LilrB2 D1D2 domains bind to Aβ but not Aβ ( Supplementary Fig. 2 ). These results indicate that the Aβ segment 16 KLVFFA 21 , which is also widely considered to be a key element of Aβ aggregation 27, 28 , is the core region that binds to LilrB2 D1D2.
We then tested the interaction of LilrB2 D1D2 with 16 KLVFFA 21 derived peptides. We did not detect binding of LilrB2 D1D2 to the peptide that contains a single copy of 16 KLVFFA 21 (Aβ 16-21 , Fig. 1 ). However, our experiment showed it did bind to a tandem repeat (TR) design of 16 KLVFFA 21 (Aβ 16-21 -TR, sequence KLVFFAPDGKLVFFA, Fig. 1 , Supplementary Table 1 ). The binding we observed with the tandem repeats was not due to introduction of the Pro-Asp-Gly linker between the two 16 KLVFFA 21 copies, because the control peptide with a single copy of 16 KLVFFA 21 and the linker (Aβ 16-21 -C, sequence KLVFFAPDG) did not bind to LilrB2 D1D2 ( Fig. 1 ). These results suggest that two copies of 16 KLVFFA 21 represent a minimal Aβ oligomer and the core epitope for LilrB2 binding. Moreover, the observation that the tandem repeat but not the single copy of 16 KLVFFA 21 binds to LilrB2 suggests that LilrB2 recognizes a particular conformation in addition to the primary amino acid sequence. We hypothesize that the antiparallel dimer of 16 KLVFFA 21 , rather than a single copy, readily assembles into a minimal oligomer, reasoning that the tandem linkage lowers the entropy barrier to oligomer formation (see Discussion).
Crystal structure of LilrB2 D1D2 complexed with benzamidine.
We mixed LilrB2 D1D2 with various Aβ segments and screened for crystals, and we determined the crystal structure of LilrB2 D1D2 mixed with Aβ 14-23 at 2.1 Å resolution (Supplementary Table 2 ). In this structure, no density for the Aβ segment was found, which is consistent with no detectable binding of 16 KLVFFA 21 monomer to LilrB2 D1D2. Instead we found four benzamidine (Ben) molecules ( Fig. 2a ), which were used as an additive for crystal optimization. The presence and positions of the benzamidine molecules were determined by inspection of difference electron density maps (F o -F c , Supplementary Fig. 3 ) and the surrounding environment ( Fig. 2b,c) . The chemical structure of benzamidine is similar to that of phenylalanine ( Fig. 2a ), so it mimics the binding of phenylalanine from the 16 KLVFFA 21 binding core of Aβ. We chose the binding pockets of Ben 3 and 4 for further investigation because of the following observations. First, the binding pockets of Ben 3 and 4 are close to each other (separated by 7.5 Å) and are both located in the groove between the D1 and D2 domains ( Fig. 2a ). Given that at least two copies of 16 KLVFFA 21 are required to bind to LilrB2 ( Fig. 1 ) and each copy has two phenylalanines, it is likely that the binding sites for 16 36 ) and crystal lattice contacts (Ben 3 with Gly 51 and Ben 4 with Leu 53 ) also stabilize benzamidine binding, but are minor contributors and appear unnecessary for binding phenylalanine. Third, Asp 36 and other negatively charged residues are located adjacent to the groove ( Supplementary Fig. 3 ), close enough to neutralize the positive charge of Lys 16 of 16 KLVFFA 21 and further stabilize its binding. Fourth, by superimposing our complex on the ligand-free LilrB2 D1D2 structure (PDB ID 2GW5 29 ), we found that, on ligand binding, the binding groove widens due to movement of the β-strand of residues 165-168. In addition, the loop composed of residues 159-164, which is disordered and lacking electron density in the ligand-free structure, becomes ordered and forms a protective cap over the binding groove ( Supplementary Fig. 3 ). These slight conformational changes make this groove a better binding site for both benzamidine and presumably the Aβ binding core. On the basis of this structural analysis, we hypothesized that the binding pockets of Ben 3 and 4 on LilrB2 are the binding sites for 16 KLVFFA 21 of Aβ; in the following we provide support for this hypothesis by mutagenesis and Rosetta docking.
Validation of the binding sites of LilrB2 by mutagenesis and
Rosetta docking. We designed three LilrB2 mutations to validate the putative binding sites for Aβ. We first chose Asn 168 and Val 38 , whose side chains participate in the Ben 3 and 4 pockets, respectively ( Fig. 2b,c ). We mutated both to tryptophan to block these two pockets by creating steric hindrance with the ligands ( Supplementary  Fig. 3 ). We also designed the D36G mutation to target Asp 36 , which ELISA-based interaction assays of Aβ42 and its constituent segments. LilrB2 D1D2 (grey bars) or bovine serum albumin as a negative control (BSA, white bars) was immobilized on ELISA plates, and incubated with Aβ segments at the concentrations shown. The unbound segments were washed off and the amounts of bound Aβ segments were measured by the Aβ-specific antibody 6E10 and quantified by absorbance at 450 nm (left axis, optical density, OD 450 ), or measured by the fluorescence signal of fluorescein (FITC) conjugated to the amino-termini of the segments and quantified by fluorescence units (right axis). Notice that for Aβ 1-42 , Aβ 1-21 and Aβ 16-21 -TR, the amounts of Aβ segments bound to LilrB2 D1D2 were significantly higher than that to BSA, indicating interaction between these segments and LilrB2 D1D2. The absence of KLVFFA from the weak binder Aβ 1-15 , as well as its presence in the stronger binders Aβ 1-21 and Aβ 16-21 -TR (sequence KLVFFAPDGKLVFFA), indicate that 16 KLVFFA 21 is the key segment of Aβ that binds to LilrB2. Segment sequences are shown in Supplementary Table 1 . Data are presented as means ± s.d. (n = 3 independent experiments). Two-sided t-tests were performed and detailed statistical analyses are reported in Supplementary Table 4 . *P < 0.05; **P < 0.005; ***P < 0.0005; NS, not significant; conc, concentration.
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putatively neutralizes the negative charge of Lys 16 of Aβ. The three resulting mutant proteins, LilrB2 D1D2 D36G, V38W and N168W, bound significantly lower amounts of full-length Aβ as well as the 16 KLVFFA 21 tandem repeat (Aβ 16-21 -TR) compared to wild type at the same loading concentration in ELISA-based interaction assays ( Fig. 3a and Supplementary Fig. 4 ). Size exclusion chromatography shows that all three mutants elute at the same retention volume as wild type ( Supplementary Fig. 4 ), and 1 H-15 N-HSQC spectra show that these mutants have similar chemical shift patterns as wild type ( Supplementary Fig. 4 ), which suggests that the diminished strength of these interactions is not due to changes in overall folding or the aggregation state of LilrB2. These results indicate that blocking Ben 3 and 4 binding pockets by single mutations diminishes the binding of LilrB2 for both full-length Aβ and the 16 KLVFFA 21 tandem repeat. Therefore, these results support our hypothesis that Ben 3 and 4 binding pockets are the binding sites for 16 KLVFFA 21 in the tandem repeat and in full-length Aβ.
To further validate the binding sites on LilrB2 and to develop a model of Aβ-LilrB2 interaction, we applied Rosetta flexible peptide docking 30 to dock the 16 KLVFFA 21 segment to LilrB2 D1D2. We used our crystal structure shown in Fig. 2 as a starting model for LilrB2. An antiparallel β-sheet unit was taken from the crystal structure of the 16 KLVFFA 21 steric zipper (PDB ID 3OW9 28 ) to represent a minimal β-sheet conformation of oligomeric Aβ 31 , and the tandem repeat of Aβ 16-21 -TR (see Discussion). During docking simulations, we confined KLVFFA to contact three key residues (Asp 36 , Val 38 and Asn 168 ) that we identified as important for Aβ binding in our mutagenesis experiments. To minimize the influence of the starting orientation of the peptide, we placed two strands of KLVFFA away from the groove between the D1 and D2 domains (putative binding site) in a random orientation. Notably, we imposed no restraints to occupy the putative binding pockets identified in our crystal structure with benzamidine. For each starting conformation, 50,000 models were generated and the top 500 models with favourable Rosetta energies were further refined by energy optimization. After refinement, the five models ranked by Rosetta energies 32 and shape complementary 33 were selected for visual inspection. We found one model with two phenylalanine residues located within the binding pockets of Ben 3 and 4 ( Fig. 3b-d ). In this model, two independent KLVFFA molecules associated as an antiparallel β-sheet and docked in the groove between D1 and D2. Phe 20 and Phe 19 from separate molecules docked in the pockets of Ben 3 and 4, respectively. The root-mean-squared deviations of the aromatic rings between phenylalanine residues and benzamidine molecules are 2.3 Å. These docking results support our prediction of LilrB2 binding sites and provide a putative model of Aβ-LilrB2 interaction. No other plausible Aβ conformation was generated by our computational docking that fits two phenylalanines in these putative LilrB2 binding sites.
Structure-based design of Aβ-LilrB2 interaction inhibitors.
We designed Aβ-LilrB2 interaction inhibitors (ALIs) to occupy the binding sites on LilrB2 and prevent Aβ binding, as directed by our structural model of the Aβ-LilrB2 complex. Our approach, adapted from previous work 34 , combines knowledge of amyloid structures and computational screening to discover small molecules that interact with Aβ fibrils and protect cells against their toxicity. We searched a compound library of ~32,000 small molecules, including approved drugs, drugs in animal tests and clinical trials, and 
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NATuRe CHemISTRy natural products whose pharmacokinetic and/or toxicity profile is known ( Supplementary Fig. 5 and Supplementary Methods). Small molecules that can potentially mimic the conformation of the aromatic rings of the ligand in our crystal structure were selected and docked to the binding pocket of LilrB2. The compounds were then ranked by their predicted binding energy and the similarity between the docked model and the crystal structure. Finally, 12 top-ranking small molecules (ALI1-12) were chosen for experimental characterization based on their shape similarity, computational docking energy and potential to cross the blood-brain barrier ( Supplementary Table 3 ). We tested the inhibitory efficiency of all candidates by quantitative immunoprecipitation assays with LilrB2 D1D2 and oligomeric Aβ42. At a molar ratio of 1:10:50 (LilrB2:Aβ:inhibitor), 9 of 12 candidates show inhibition of the Aβ-LilrB2 interaction with a lower Aβ binding signal that was considered to be statistically significant compared to the controls with no inhibitor added (Fig. 4a ). Six candidates (ALI4, 5, 6, 7, 9 and 10) were selected for concentration-dependent studies, and all inhibited the Aβ-LilrB2 interaction in a dose-dependent manner ( Fig. 4b and Supplementary Fig. 6 ). Their docking models, created by high-resolution Rosetta docking, were superimposed with benzamidine and are shown in Fig.  4c and Supplementary Fig. 6 . Statistical analysis of the concentration-dependent studies shows that all six candidates have a high nanomolar to low micromolar K i and low micromolar IC 50 values (Fig. 4d) . These results suggest that our structure-based design was successful in identifying small molecule inhibitors that block the Aβ-LilrB2 interaction in vitro.
Tests of inhibitors by cell-based assays.
To test the inhibitors on cells, we transiently transfected HEK293T cells with full-length LilrB2 with monomer red fluorescent protein (mRFP) conjugated at its carboxy terminus (LilrB2-mRFP). We then tested the interaction of LilrB2 with exogenously added oligomeric Aβ42 conjugated at its amino Supplementary Fig. 4 ), and incubated with Aβ 1-42 or Aβ 16-21 -TR at concentrations indicated under each histogram. The amounts of bound Aβ 1-42 were measured by antibody 6E10 and quantified by absorbance at 450 nm (OD 450 , left axis), and the amounts of bound Aβ 16-21 -TR were measured by the fluorescence signal of fluorescein and quantified by fluorescence units (right axis). Data are presented as means ± s.d. (n = 3 independent experiments, ***P < 0.0005, ANOVA test); conc, concentration. For detailed statistical analysis see Supplementary Table 4 . b-d, Model of two KLVFFA peptides binding to LilrB2 D1D2 calculated by Rosetta docking. In this model, Phe 20 from one KLVFFA chain and Phe 19 from another chain bind to Ben 3 (d, left) and Ben 4 (d, right) pockets, respectively. Three residues tested in mutagenesis studies (Asp 36 , Val 38 and Asn 168 ) were used as restraints in Rosetta docking. Residue colours correspond to the key in a.
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terminus with fluorescein (FITC-Aβ42, Supplementary Fig. 7 ). HEK293T cells transfected with mRFP alone were used as negative control. After 3 h of incubation with FITC-Aβ42, we fixed and washed the cells, and found that cells transfected with mRFP bind only 13% of FITC-Aβ42 relative to cells transfected with LilrB2-mRFP ( Fig. 5a,b) , consistent with previously reported results using HEK293 cells expressing LilrB2 or PirB 26 . These results indicate that LilrB2 induces Aβ-cell interaction. When we added a 10 µ M concentration of our inhibitors to cells before adding FITC-Aβ42, we found the amount of bound Aβ42 was significantly reduced;
the lowest values were 27% (ALI10) and 29% (ALI6) relative to the controls in which no inhibitor was added ( Fig. 5a,b) . These results indicate that our selected small molecules inhibit the Aβ-LilrB2 interaction at the cellular level, and therefore inhibit LilrB2-induced Aβ-cell contact.
We selected candidate compound ALI6 to examine its effect on the cytotoxicity of Aβ, because ALI6 exhibits the best score in the computational docking and the best inhibitory activity both in vitro and on cell levels. We transfected HEK293T cells with LilrB2-mRFP and treated them with 500 nM oligomeric Aβ42 for Supplementary Fig. 6 . In the immunoprecipitation assays in b and d, data are presented as mean ± s.d., n = 3 independent experiments.
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NATuRe CHemISTRy 24 h. Cell viability (MTT) assays showed that 38% of cells were killed relative to controls in which the cells were incubated with PBS buffer solutions (Fig. 5c ). Further cell viability assays established that ALI6 rescues the cells in a dose-dependent manner. When the cells were treated with ALI6 5 min before adding Aβ42, 1 µ M ALI6 reduced the cell death to 30%, 2 µ M ALI6 reduced the cell death to 24%, 5 µ M ALI6 reduced the cell death to 8% and 10 µ M ALI6 reduced the cell death to 7%. Moreover, 10 µ M ALI6 in the absence of Aβ42 showed no effect on cell viability. These results suggest that ALI6 inhibits Aβ cytotoxicity.
Validation of ALI6 with primary neurons. Primary neuron models have been widely used to test Aβ cytotoxicity and the effect of Aβ inhibitors, and two known inhibitors of Aβ, curcumin 35 and (-)-epigallocatechin-3-gallate (EGCG) 36 , have been reported to rescue the neurotoxic effects of Aβ. We further validated the effect of ALI6 with mouse primary neurons. Cells from cortices dissected at embryonic day 15 were dispersed and cultured for 14 days in vitro (DIV14). Mouse cortical neurons have previously been shown to express PirB at DIV14 37 . Cells were then treated with 500 nM FITC-Aβ42 to assess Aβ binding. We found that cells pretreated with 10 µ M ALI6 bound 39.0 ± 20.5% (mean ± s.d.) of FITC-Aβ42 compared to cells pretreated with the same amount of DMSO (Fig. 6a,b) , indicating that ALI6 inhibits the binding of Aβ to neurons. The observation that ALI6 does not fully inhibit Aβ binding, even at a higher dose (50 µ M ALI6 bound 49.9 ± 12.3% FITC-Aβ42, Fig. 6b ), indicates that there are Aβ receptors other than LilrB2 on the neuronal cell surface, consistent with the observation of Aβ42 binding to neuron cells from PirB −/− mice at 50% the level of wild-type neurons 26 .
Although the binding of Aβ was not fully eliminated, we found that ALI6 is sufficient in inhibiting Aβ cytotoxicity in primary neurons, similar to curcumin 35 and EGCG 36 . Using terminal deoxynucleotidyl transferase-dUTP nick end labelling (TUNEL) assays to detect apoptotic DNA fragmentation, we found that 50.1 ± 4.3% of the cells treated with Aβ42 and DMSO undergo cell death (Fig. 6c,d) . When DMSO was substituted with same amount of ALI6 (5 µ M), cell death dropped to 16.5 ± 8.9%, equivalent to the vehicle control (11.9 ± 11.4%) and ALI6 alone (11.0 ± 11.6%). These results support the potential of ALI6 for rescuing Aβ-caused neuron damage. Supplementary Table 4 .
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We further tested the effect of ALI6 on the downstream pathway of LilrB2. A previous study proposed that Aβ-LilrB2 interaction causes dephosphorylation of cofilin, an actin-depolymerizing factor, leading to eventual synapse loss 26 . Indeed, the same study showed the ratio of phosphorylated cofilin (p-cofilin) to total cofilin decreasing in primary neurons treated with Aβ. Here, we also found that on treatment with 150 nM Aβ42 for 1 h, the p-cofilin/cofilin level in primary neurons dropped to 67.5 ± 8.1% of the value seen in cells treated with vehicle alone (Fig. 6e ). When pretreated with 3 µ M ALI6, the p-cofilin/cofilin level was restored to 101.5 ± 7.4% relative to vehicle-treated cells. These results indicate ALI6 protects neurons from Aβ-induced changes in the cofilin signalling pathway, and further support the therapeutic potential of ALI6.
Discussion
Our interaction assays confirm previous reports that LilrB2 recognizes Aβ oligomers 26 , and suggest a molecular mechanism for the specificity of recognition. We first mapped the binding core to the segment 16 KLVFFA 21 of Aβ and tested two binding epitopes: a tandem repeat of 16 KLVFFA 21 (Aβ 16-21 -TR) designed to spontaneously self-assemble into an antiparallel β-sheet, and a single-copy peptide (Aβ 16-21 -C), which we presume remains single stranded in solution under the conditions tested due to an entropy barrier to oligomer formation. We found that LilrB2 binds to the tandem repeat but not to the single strand ( Fig. 1 ), suggesting that LilrB2 recognizes an antiparallel β-sheet conformation specific to Aβ oligomers 31 .
Several lines of evidence support our hypothesis that Aβ 16-21 -TR is a better mimic of the full-length Aβ oligomer than is Aβ 16-21 -C. Aβ42 binding was quantified as the integrated intensity of green fluorescence in each well, normalized to cell confluency in the same well, and then presented as a percentage relative to cells treated with FITC-Aβ42 and DMSO (**P < 0.005, ANOVA test). c, Bright-field and fluorescence images of primary neuron cells treated with 300 nM Aβ42 and 5 µ M ALI6 or equal amounts of DMSO, or treated with PBS and DMSO as vehicle control. Cell viability was measured by TUNEL assays, and dead cells are shown as red puncta. d, Quantification of TUNEL cell viability assays. Cell viability is shown as a percentage of cell death calculated as the number of red puncta divided by the number of blue puncta (Hoechst stain) (***P < 0.0005, two-sided t-test). e, Primary neuron cells were treated with 150 nM Aβ42 with 3 µ M ALI6 or equal amounts of DMSO, and cofilin signalling levels were analysed by western blot (left). Anti-tubulin β-3 antibody detects neuronal tubulin and was used as a loading control. Quantification of cofilin phosphorylation (right) was calculated as the intensity of the phosphorylated cofilin band divided by the intensity of the cofilin band, and was normalized to cells treated with PBS and DMSO (vehicle control) (**P < 0.005, two-sided t-test). Data are presented as means ± s.d. (n = 4 independent experiments). For a detailed statistical analysis see Supplementary Table 4 .
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Aβ 16-21 -TR has more β-strand content than Aβ 16-21 -C, as indicated by a higher ellipticity (circular dichroism) value measured at 200 nm for the peptides linked to the 5x arginine tag (this tag was needed to achieve sufficient solubility) ( Supplementary Fig. 2 and Supplementary Table 1 ). Analysis of the circular dichroism spectra also showed that the β-strand (antiparallel) content of Aβ 16-21 -TR is higher (33%) than that of Aβ 16-21 -C (28%). Moreover, when incubated at 37 °C at high concentration (2 mM), Aβ 16-21 -TR formed fibres but Aβ 16-21 -C did not ( Supplementary Fig. 2 ). Presuming that fibrillar and oligomeric species share common structural features, these results suggest that Aβ 16-21 -TR better mimics the full-length Aβ oligomer, and explain our observation that it is a better epitope for LilrB2. Finally, the Rosetta docking experiments using as input the steric zipper structure of KLVFFA successfully generated a model that agrees with our LilrB2-benzamidine complex structure within the top 0.1% of Rosetta energy rankings. These results support our previous hypothesis that β-sheets are not only characteristic of amyloid fibres 38 but also of oligomers 39, 40 .
The transient and heterogeneous nature of Aβ oligomers makes their structural elucidation extremely challenging. The observation that LilrB2 binds to Aβ oligomers with a wide range of sizes ( Supplementary Fig. 2 ) also indicates the difficulty of characterizing the structure of an Aβ oligomer-LilrB2 complex. To gain insights into the structure of this complex, we first narrowed the binding core of Aβ to a six-residue segment ( 16 KLVFFA 21 ), and identified its binding site on LilrB2 through the structure of LilrB2 with a small molecule that mimics the phenylalanine side chains of the Aβ binding core. The binding sites were validated by mutagenesis and Rosetta docking, and then used for structure-based inhibitor design. Our results show that the LilrB2 D1D2-benzamidine complex structure we determined provides a platform sufficient for inhibitor development of the Aβ-LilrB2 interaction.
In addition to LilrB2, other putative Aβ receptors have been reported to bind Aβ oligomers and cause neuronal damage 25 . Our rationale for choosing LilrB2 as a target for inhibitor design is that an animal model shows that mice lacking PirB (the murine homologue of LilrB2) are immune to the damaging effects of Aβ in hippocampal long-term potentiation (LTP) and memory 26 . One reason to suppose that blocking only the LilrB2 receptor might be sufficient to inhibit Aβ toxicity is that blockade of one high-affinity Aβ receptor may sufficiently reduce the contact of Aβ with cells. This hypothesis is supported by the observation that Aβ42 oligomer binding to cultured cortical neurons from PirB -/mice is diminished by about 50% relative to wild-type neurons 26 . In AD patients, this reduction may be sufficient to move the equilibrium from Aβ-cell contact to Aβ clearance 41 , thus inhibiting Aβ-triggered neuronal toxicity. Our cell viability assays on primary neurons support this hypothesis, which show ALI6 can almost completely block the effect of Aβ (Fig. 6d ). Further study is required to identify the possibility that our inhibitor can also work on other Aβ receptors.
Compared to other AD drug development strategies that target Aβ aggregation [15] [16] [17] or bind monomeric Aβ with antibody 42 , targeting Aβ oligomer is advantageous because the inhibitor does not need to be added before Aβ aggregation. When testing the inhibition of Aβ cytotoxicity, Aβ monomer or aggregation targeting inhibitors need to be co-incubated with Aβ from the beginning of Aβ aggregation 15 , so presumably these inhibitors can only treat early-stage AD patients before massive Aβ aggregation forms. This may be part of the reason why solanezumab, an antibody targeting monomeric Aβ, failed in a recent clinical trial 43 . In comparison, all of our inhibition experiments were done by separately adding inhibitors and preformed Aβ oligomer, offering the possibility of treating patients that already have Aβ aggregation in their brains.
The structure-based approach has been shown to be a powerful tool for drug development 5, 44 . In this study, we computationally identified 12 candidate inhibitors by structure-guided selection. Nine out of 12 candidates show inhibition of the Aβ-LilrB2 interaction in vitro; six candidates were selected for further testing, and all of them exhibit low micromolar to high nanomolar K i and IC 50 values. These inhibitors eliminate the effects of Aβ-LilrB2 binding on the cell surface, and candidate ALI6 inhibits Aβ binding and cytotoxicity to primary neurons. Our results support the hypothesis that blocking this Aβ-receptor interaction is a potential way to inhibit Aβ toxicity and prevent neuron damage, and that LilrB2 is a promising therapeutic target. In addition, the compound library we used for computational inhibitor selection is composed of approved drugs, drugs in animal tests and clinical trials, and natural products whose pharmacokinetic and/or toxicity profile is known. During the inhibitor selection process, we also checked the potential of the selected compounds to cross the blood-brain barrier (Supplementary Table 3 ). This strategy ensures that our selected inhibitors, for example, ALI6, are safe for human use and are able to cross the blood-brain barrier. These properties make these inhibitors useful tools in further investigating the role of LilrB2 in the pathogenesis of AD, and qualifies them as promising candidates for expediting further AD drug development. We also note that the concentrations of inhibitors we used are high and might be difficult to achieve in vivo. Our proof-of-concept study provides several promising starting points for drug development, and further work is needed to improve the affinity of these inhibitors to increase their translational values.
Methods
The methods and materials used in this study are available in the Supplementary Information. 
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